Edgewise Therapeutics Inc

NASDAQ:EWTXUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. It has built its muscle-focused drug discovery platform. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. Its lead product candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. Its product candidate, EDG-7500, for the treatment of hypertrophic cardiomyopathy addition to exploring the potential of its mechanism in the treatment of disorders of diastolic dysfunction.

Contact Information

Headquarters

1715 38Th StBOULDER, CO, United States 80301

Phone

720-262-7002

Fax

302-636-5454

Executives

Co-Founder, Director

Peter Thompson

President, Chief Executive Officer, Director

Kevin Koch

Co-Founder, Chief Scientific Officer

Alan Russell

Co-Founder, Independent Director

Badreddin Edris

Chief Financial Officer

R. Michael Carruthers